bioAffinity appoints three lung cancer specialists to Medical and Scientific Advisory Board

bioAffinity Technologies, Inc.

David Ost (MD Anderson), Daniel Sterman (NYU Langone) and J. Scott Ferguson (Univ. of Wisconsin) joined the advisory board.
Advisory board provides guidance on clinical priorities and broader adoption of CyPath® Lung diagnostic test.
CyPath® Lung is a noninvasive test for early lung cancer detection with 92% sensitivity and 87% specificity in clinical studies.
New appointees join current members including David Hill, Neil Alexis, Sheila Habib, and Sandeep Bansal.
Company says appointments align with its focus on integrating CyPath® Lung into standard care for indeterminate pulmonary nodules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.